Cell cycle kinases (AUKA, CDK1, PLK1) are prognostic biomarkers and correlated with tumor-infiltrating leukocytes in HBV related HCC

References

• Bandopadhyay, M., & Bharadwaj, M. (2020). Exosomal miRNAs in hepatitis B virus related liver disease: a new hope for biomarker. Gut Pathogens, 12(1), 1-16. https://doi.org/10.1186/s13099-020-00353-w
   PubMed Web of Science ®Google Scholar
• Benson, A. B., D'Angelica, M. I., Abbott, D. E., Abrams, T. A., Alberts, S. R., Anaya, D. A., Anders, R., Are, C., Brown, D., Chang, D. T., Cloyd, J., Covey, A. M., Hawkins, W., Iyer, R., Jacob, R., Karachristos, A., Kelley, R. K., Kim, R., Palta, M., … Darlow, S. D. (2019). Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. Journal of the National Comprehensive Cancer Network : JNCCN, 17(4), 302–310. https://doi.org/10.6004/jnccn.2019.0019
   PubMed Web of Science ®Google Scholar
• Crane, R., Gadea, B., Littlepage, L., Wu, H., & Ruderman, J. V. (2004). Aurora A, Meiosis and Mitosis. Biology of the Cell, 96(3), 215–229. https://doi.org/10.1016/j.biolcel.2003.09.008
   PubMed Web of Science ®Google Scholar
• Deng, J., Zhong, F., Gu, W., & Qiu, F. (2021). Exploration of prognostic biomarkers among replication factor C family in the hepatocellular carcinoma. Evolutionary Bioinformatics Online, 17, 1176934321994109. https://doi.org/10.1177/1176934321994109
   Web of Science ®Google Scholar
• Ding, X., Duan, H., & Luo, H. (2020). Identification of core gene expression signature and key pathways in colorectal cancer. Frontiers in Genetics, 11, 45. https://doi.org/10.3389/fgene.2020.00045
   PubMedGoogle Scholar
• Hsiao, Y. W., Chiu, L. T., Chen, C. H., Shih, W. L., & Lu, T. P. (2019). Tumor-infiltrating leukocyte composition and prognostic power in hepatitis B- and hepatitis C-related hepatocellular carcinomas. Genes, 10(8), 630. https://doi.org/10.3390/genes10080630
   PubMed Web of Science ®Google Scholar
• Jia, L., Gao, Y., He, Y., Hooper, J. D., & Yang, P. (2020). HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacological Research, 159, 104992. https://doi.org/10.1016/j.phrs.2020.104992
   PubMed Web of Science ®Google Scholar
• Jiang, Y., Han, Q., Zhao, H., & Zhang, J. (2021). The mechanisms of HBV-induced hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 8, 435–450. volumehttps://doi.org/10.2147/JHC.S307962
   PubMed Web of Science ®Google Scholar
• Joukov, V., & De Nicolo, A. (2018). Aurora-PLK1 cascades as key signaling modules in the regulation of mitosis. Science signaling, 11(543), eaar4195.
   Google Scholar
• Jung, J. K., Arora, P., Pagano, J. S., & Jang, K. L. (2007). Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Research, 67(12), 5771–5778. https://doi.org/10.1158/0008-5472.CAN-07-0529
   PubMed Web of Science ®Google Scholar
• Jung, J. K., Park, S. H., & Jang, K. L. (2010). Hepatitis B virus X protein overcomes the growth-inhibitory potential of retinoic acid by downregulating retinoic acid receptor-beta2 expression via DNA methylation. The Journal of General Virology, 91(Pt 2), 493–500. https://doi.org/10.1099/vir.0.015149-0
   PubMedGoogle Scholar
• Konyn, P., Ahmed, A., & Kim, D. (2021). Current epidemiology in hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology, 15(11), 1295–1307. https://doi.org/10.1080/17474124.2021.1991792
   PubMed Web of Science ®Google Scholar
• Kuss-Duerkop, S. K., Westrich, J. A., & Pyeon, D. (2018). DNA tumor virus regulation of host DNA methylation and its implications for immune evasion and oncogenesis. Viruses, 10(2), 82. https://doi.org/10.3390/v10020082
   PubMed Web of Science ®Google Scholar
• Lee, S.-M., Lee, Y-g., Bae, J.-B., Choi, J. K., Tayama, C., Hata, K., Yun, Y., Seong, J.-K., & Kim, Y.-J. (2014). HBx induces hypomethylation of distal intragenic CpG islands required for active expression of developmental regulators. Proceedings of the National Academy of Sciences of the United States of America, 111(26), 9555–9560. https://doi.org/10.1073/pnas.1400604111
   PubMed Web of Science ®Google Scholar
• Li, L., Huang, K., Zhao, H., Chen, B., Ye, Q., & Yue, J. (2020). CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma. Cell Cycle, 19(10), 1236-1252. https://doi.org/10.1080/15384101.2020.1749471.
   Google Scholar
• Li, R., Jiang, X., Zhang, Y., Wang, S., Chen, X., Yu, X., Ma, J., & Huang, X. (2019). Cyclin B2 overexpression in human hepatocellular carcinoma is associated with poor prognosis. Archives of Medical Research, 50(1), 10–17. https://doi.org/10.1016/j.arcmed.2019.03.003
   PubMed Web of Science ®Google Scholar
• Li, X., Martinez-Ledesma, E., Zhang, C., Gao, F., Zheng, S., Ding, J., Wu, S., Nguyen, N., Clifford, S. C., Wen, P. Y., Ligon, K. L., Yung, W. K. A., & Koul, D. (2019). Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating aurora A/PLK1/CDK1 signaling in glioblastoma. Cancer Research, 79(19), 5088–5101. https://doi.org/10.1158/0008-5472.CAN-19-0325
   PubMed Web of Science ®Google Scholar
• Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016). Hepatocellular carcinoma. Nature Reviews. Disease Primers, 2, 16018. https://doi.org/10.1038/nrdp.2016.18
   PubMed Web of Science ®Google Scholar
• Macůrek, L., Lindqvist, A., Lim, D., Lampson, M. A., Klompmaker, R., Freire, R., Clouin, C., Taylor, S. S., Yaffe, M. B., & Medema, R. H. (2008). Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature, 455(7209), 119–123. https://doi.org/10.1038/nature07185
   PubMed Web of Science ®Google Scholar
• Malumbres, M., & Barbacid, M. (2005). Mammalian cyclin-dependent kinases. Trends in Biochemical Sciences, 30(11), 630–641. https://doi.org/10.1016/j.tibs.2005.09.005
   PubMed Web of Science ®Google Scholar
• Mignogna, C., Staropoli, N., Botta, C., De Marco, C., Rizzuto, A., Morelli, M., Di Cello, A., Franco, R., Camastra, C., Presta, I., Malara, N., Salvino, A., Tassone, P., Tagliaferri, P., Barni, T., Donato, G., & Di Vito, A. (2016). Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. Journal of Ovarian Research, 9(1), 31. https://doi.org/10.1186/s13048-016-0238-7
   PubMedGoogle Scholar
• Najafi, M., Farhood, B., & Mortezaee, K. (2019). Contribution of regulatory T cells to cancer: A review. Journal of Cellular Physiology, 234(6), 7983–7993. https://doi.org/10.1002/jcp.27553
   PubMed Web of Science ®Google Scholar
• Novitasari, D., Jenie, R. I., Kato, J. Y., & Meiyanto, E. (2021). The integrative bioinformatic analysis deciphers the predicted molecular target gene and pathway from curcumin derivative CCA-1.1 against triple-negative breast cancer (TNBC). Journal of the Egyptian National Cancer Institute, 33(1), 19. https://doi.org/10.1186/s43046-021-00077-1
   PubMed Web of Science ®Google Scholar
• Park, S. H., Jung, J. K., Lim, J. S., Tiwari, I., & Jang, K. L. (2011). Hepatitis B virus X protein overcomes all-trans retinoic acid-induced cellular senescence by downregulating levels of p16 and p21 via DNA methylation. The Journal of General Virology, 92(Pt 6), 1309–1317. https://doi.org/10.1099/vir.0.029512-0
   PubMedGoogle Scholar
• Park, I. Y., Sohn, B. H., Yu, E., Suh, D. J., Chung, Y.-H., Lee, J.-H., Surzycki, S. J., & Lee, Y. I. (2007). Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology, 132(4), 1476–1494. https://doi.org/10.1053/j.gastro.2007.01.034
   PubMed Web of Science ®Google Scholar
• Pellegrino, R., Calvisi, D. F., Ladu, S., Ehemann, V., Staniscia, T., Evert, M., Dombrowski, F., Schirmacher, P., & Longerich, T. (2010). Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology (Baltimore, Md.), 51(3), 857–868. https://doi.org/10.1002/hep.23467
   PubMed Web of Science ®Google Scholar
• Petrizzo, A., Mauriello, A., Tornesello, M. L., Buonaguro, F. M., Tagliamonte, M., & Buonaguro, L. (2018). Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. Infectious Agents and Cancer, 13, 10. https://doi.org/10.1186/s13027-018-0183-8
   PubMed Web of Science ®Google Scholar
• Qiang, R., Zhao, Z., Tang, L., Wang, Q., Wang, Y., & Huang, Q. (2021). Identification of 5 hub genes related to the early diagnosis, tumour stage, and poor outcomes of hepatitis B virus-related hepatocellular carcinoma by bioinformatics analysis. Computational and Mathematical Methods in Medicine, 2021, 9991255. https://doi.org/10.1155/2021/9991255
   PubMed Web of Science ®Google Scholar
• Roskoski, R. Jr. (2019). Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacological Research, 139, 471–488. https://doi.org/10.1016/j.phrs.2018.11.035
   PubMed Web of Science ®Google Scholar
• Song, G., Zhu, X., Xuan, Z., Zhao, L., Dong, H., Chen, J., Li, Z., Song, W., Jin, C., Zhou, M., Xie, H., Zheng, S., & Song, P. (2021). Hypermethylation of GNA14 and its tumor-suppressive role in hepatitis B virus-related hepatocellular carcinoma. Theranostics, 11(5), 2318–2333. https://doi.org/10.7150/thno.48739
   PubMed Web of Science ®Google Scholar
• Wang, B., Hsu, C.-J., Chou, C.-H., Lee, H.-L., Chiang, W.-L., Su, C.-M., Tsai, H.-C., Yang, S.-F., & Tang, C.-H. (2018). Variations in the AURKA gene: Biomarkers for the development and progression of hepatocellular carcinoma. International Journal of Medical Sciences, 15(2), 170–175. https://doi.org/10.7150/ijms.22513
   PubMed Web of Science ®Google Scholar
• Xi, S., Zhao, X., Liu, W., Wang, Y., Cao, J., Liu, B., & Dou, J. (2020). Bioinformatics analysis to reveal key biomarkers for early and late hepatocellular carcinoma. Translational Cancer Research, 9(7), 4070–4079. https://doi.org/10.21037/tcr-19-2238
   PubMed Web of Science ®Google Scholar
• Xie, Q., Chen, L., Shan, X., Shan, X., Tang, J., Zhou, F., Chen, Q., Quan, H., Nie, D., Zhang, W., Huang, A.-L., & Tang, N. (2014). Epigenetic silencing of SFRP1 and SFRP5 by hepatitis B virus X protein enhances hepatoma cell tumorigenicity through Wnt signaling pathway. International Journal of Cancer, 135(3), 635–646. https://doi.org/10.1002/ijc.28697
   PubMed Web of Science ®Google Scholar
• Yan, Y., Huang, P., Mao, K., He, C., Xu, Q., Zhang, M., Liu, H., Zhou, Z., Zhou, Q., Zhou, Q., Ou, B., Liu, Q., Lin, J., Chen, R., Wang, J., Zhang, J., & Xiao, Z. (2021). Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression. Oncogene, 40(1), 28–45. https://doi.org/10.1038/s41388-020-01498-3
   PubMed Web of Science ®Google Scholar
• Yang, P., Li, Q.-J., Feng, Y., Zhang, Y., Markowitz, G. J., Ning, S., Deng, Y., Zhao, J., Jiang, S., Yuan, Y., Wang, H.-Y., Cheng, S.-Q., Xie, D., & Wang, X.-F. (2012). TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell, 22(3), 291–303. https://doi.org/10.1016/j.ccr.2012.07.023
   PubMed Web of Science ®Google Scholar
• Yang, P., Markowitz, G. J., & Wang, X.-F. (2014). The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. National Science Review, 1(3), 396–412. https://doi.org/10.1093/nsr/nwu038
   PubMed Web of Science ®Google Scholar
• Yang, Q., Sun, C., Sheng, Y., Chen, W., & Deng, C. (2022). The biomarkers for predicting viral hepatitis associated hepatocellular carcinoma. The Turkish Journal of Gastroenterology : The Official Journal of Turkish Society of Gastroenterology, 33(1), 1–7. https://doi.org/10.5152/tjg.2022.19813
   PubMed Web of Science ®Google Scholar
• Zahra, A., Kerslake, R., Kyrou, I., Randeva, H. S., Sisu, C., & Karteris, E. (2022). Impact of environmentally relevant concentrations of bisphenol A (BPA) on the gene expression profile in an in vitro model of the normal human ovary. International Journal of Molecular Sciences, 23, 5334. https://doi.org/10.3390/ijms23105334.
   Web of Science ®Google Scholar
• Zhang, H., Bao, J., Zhao, S., Huo, Z., & Li, B. (2020). MicroRNA-490-3p suppresses hepatocellular carcinoma cell proliferation and migration by targeting the aurora kinase A gene (AURKA). Archives of Medical Science : AMS, 16(2), 395–406. https://doi.org/10.5114/aoms.2019.91351
   PubMed Web of Science ®Google Scholar
• Zhang, L., Huang, Y., Ling, J., Zhuo, W., Yu, Z., Shao, M., Luo, Y., & Zhu, Y. (2018). Screening and function analysis of hub genes and pathways in hepatocellular carcinoma via bioinformatics approaches. Cancer Biomarkers : Section A of Disease Markers, 22(3), 511–521. https://doi.org/10.3233/CBM-171160
   PubMed Web of Science ®Google Scholar
• Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y., & Zhang, Y. T. (2020). Cell dysfunction and exhaustion in cancer. Frontiers in Cell and Developmental Biology, 8, 17.
   PubMed Web of Science ®Google Scholar
• Zhao, Z., Hu, Y., Shen, X., Lao, Y., Zhang, L., Qiu, X., Hu, J., Gong, P., Cui, H., Lu, S., Zheng, Y., Zhou, M., & Fan, H. (2017). HBx represses RIZ1 expression by DNA methyltransferase 1 involvement in decreased miR-152 in hepatocellular carcinoma. Oncology Reports, 37(5), 2811–2818. https://doi.org/10.3892/or.2017.5518
   PubMed Web of Science ®Google Scholar
• Zhou, J., Han, S., Qian, W., Gu, Y., Li, X., & Yang, K. (2018). Metformin induces miR-378 to downregulate the CDK1, leading to suppression of cell proliferation in hepatocellular carcinoma. OncoTargets and Therapy, 11, 4451–4459. https://doi.org/10.2147/OTT.S167614
   PubMed Web of Science ®Google Scholar
• Zou, Y., Ruan, S., Jin, L., Chen, Z., Han, H., Zhang, Y., Jian, Z., Lin, Y., Shi, N., & Jin, H. (2020). CDK1, CCNB1, and CCNB2 are Prognostic Biomarkers and Correlated with Immune Infiltration in Hepatocellular Carcinoma. Medical science monitor: international medical journal of experimental and clinical research, 26, e925289. https://doi.org/10.12659/MSM.925289
   Google Scholar